<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01454661</url>
  </required_header>
  <id_info>
    <org_study_id>ETMK 104/180/2011</org_study_id>
    <nct_id>NCT01454661</nct_id>
  </id_info>
  <brief_title>Probiotics and Early Microbial Contact in Preterm Neonates</brief_title>
  <acronym>ProPre</acronym>
  <official_title>Probiotic Modulation of Early Microbial Contact in Premature Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Turku</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Turku University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Probiotics are live microbes which, when administered in sufficient amounts, confer a health
      benefit to the host. According to recent clinical trials, administration of probiotics to
      very low birth weight infants significantly reduces overall mortality and risk of necrotizing
      enterocolitis, a devastating inflammatory intestinal disease. The investigators have
      previously demonstrated that administering probiotics to the lactating mother enhances the
      immunoprotective properties of breast milk. Despite the promising data, the optimal probiotic
      intervention is yet to be established. The mechanisms by which probiotics exert their effects
      remain largely unknown.

      This research project is based on the notion that modulation of early microbial contact by
      probiotics may provide a safe and effective means to improve the health of preterm infants.
      In particular, the investigators hypothesize that the protective potential of probiotics may
      be enhanced via breast milk by administering probiotics to the lactating mother. All of the
      potentially beneficial effects of probiotic bacteria are strain-specific and therefore
      preliminary laboratory and clinical research with regard to different physiological targets
      of probiotic intervention should be carried out to guide the design of large-scale clinical
      trials aiming show clinical efficacy and establish clinical practice. The purpose of this
      research project is to identify targets for probiotic therapy in premature neonates and to
      provide insight into the optimal probiotic strains and administration protocol the clinical
      efficacy of which will subsequently be tested in a randomized controlled trial.

      The specific aims of the project are:

        1. To determine the effect of maternal consumption of probiotics during lactation on
           immunomodulatory properties of breast milk in mothers of premature infants.
           Concentrations of immunomodulatory factors and microbiological properties of breast milk
           will be measured.

        2. To investigate the impact of different probiotic administration protocols on gut
           microbiota composition in preterm infants. In particular, the issue whether maternal
           probiotic consumption instead or in addition to probiotics administered to the infant is
           effective will be elucidated. Different potential probiotic strains will be assessed.

        3. To elucidate the impact probiotic bacteria administered to the lactating mother and/or
           directly to the infant on gut immunophysiology in preterm infants.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gut microbiota</measure>
    <time_frame>1 month</time_frame>
    <description>Assessment of indigenous intestinal microbiota composition in premature neonates during the first month of life</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intestinal immunity</measure>
    <time_frame>1 month</time_frame>
    <description>Intestinal immune gene expression profiles will be assessed from fecal samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breast milk compostion</measure>
    <time_frame>1 months</time_frame>
    <description>Immunological and microbiological properties of breast milk will be investigated.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Premature; Infant, Light-for-dates</condition>
  <condition>Breastfeeding</condition>
  <arm_group>
    <arm_group_label>placebo mother - LGG infant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo is administered to the lactating mother whilst the infant receives the probiotic LGG.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo mother - placebo infant</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo is administered to both the lactating mother and her infant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LGG mother - placebo infant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The probiotic LGG is administered to the lactating mother whilst the infant receives placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LGG+Bb-12 mother - Placebo infant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A combination of the probiotics LGG and Bb-12 is administered to the lactating mother, the infant receives placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pacebo mother - LGG+Bb-12 infant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo is administered to the lactating mother, the infant receives a combination of the probiotics LGG and Bb-12</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>LGG</intervention_name>
    <description>Lactobacillus rhamnosus GG 10E9 cfu / day</description>
    <arm_group_label>placebo mother - LGG infant</arm_group_label>
    <arm_group_label>LGG mother - placebo infant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>LGG+Bb-12</intervention_name>
    <description>A combination of the probiotics Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb-12 administered 10E9 cfu / day each.</description>
    <arm_group_label>LGG+Bb-12 mother - Placebo infant</arm_group_label>
    <arm_group_label>Pacebo mother - LGG+Bb-12 infant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Microcrystalline cellulose is used as placebo.</description>
    <arm_group_label>placebo mother - placebo infant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  premature infant born at &lt;35 weeks gestational age

        Exclusion Criteria:

          -  severe asphyxia

          -  significant anomalies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>3 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuli Rautava, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Turku University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Samuli Rautava, MD, PhD</last_name>
    <phone>+358 40 7033166</phone>
    <email>samrau@utu.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samuli Rautava, MD, PhD</last_name>
      <phone>+358 40 7033166</phone>
      <email>samrau@utu.fi</email>
    </contact>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2011</study_first_submitted>
  <study_first_submitted_qc>October 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2011</study_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Turku University Hospital</investigator_affiliation>
    <investigator_full_name>Samuli Rautava</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Probiotics</keyword>
  <keyword>Premature infant</keyword>
  <keyword>Intestinal microbiota</keyword>
  <keyword>Intestinal immunity</keyword>
  <keyword>Breastfeeding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

